Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

facturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to fund operations through the primary endpoint analysis of its Phase 3 clinical registration trial progress and timing of clinical trials for Specifid, including difficulties or delays in development, testing, manufacturing and marketing Specifid or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for Specifid or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of Specifid and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of Specifid for use in clinical trials and, if Specifid receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using Specifid; potential delays in patient enrollme
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... 28, 2014 It’s a hard truth: Nearly ... to further their post-secondary education are failing to obtain a ... this year. And according to an analysis by The ... veteran students’ uninformed choice of college majors, which leads to ... the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... July 28, 2014 The global market ... by 2020, according to a new study by Grand ... rising demand for effective vaccines and drugs in an ... medical needs is expected to drive market demand over ... enhance agricultural productivity via the use of genetically engineered ...
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4InterMune to Release Second Quarter Financial Results on August 6 2
... , , , , , ... in eukaryotic cell cultures , requires double-stranded molecules known ... licensed supplier of siRNA, offering a custom , ... directed against common target genes, and a Cancer , ...
... For transfection of eukaryotic cells with RNA and siRNA , , , , , , ... Kit Contents , Storage and Stability ... Technical Assistance , Product Use Limitations ... Safety Information , ...
... QIAshredder spin columns are designed for simple and rapid homogenization , of cell and tissue lysates. ... , , Format: , ... , , Sample source: , ... plant cell or tissue lysates, white blood cell lysates, , ...
Cached Biology Technology:RNAi Gene Silencing System 2RNAi Gene Silencing System 3TransMessenger Transfection Reagent Handbook 2TransMessenger Transfection Reagent Handbook 3TransMessenger Transfection Reagent Handbook 4TransMessenger Transfection Reagent Handbook 5TransMessenger Transfection Reagent Handbook 6TransMessenger Transfection Reagent Handbook 7TransMessenger Transfection Reagent Handbook 8TransMessenger Transfection Reagent Handbook 9TransMessenger Transfection Reagent Handbook 10TransMessenger Transfection Reagent Handbook 11TransMessenger Transfection Reagent Handbook 12TransMessenger Transfection Reagent Handbook 13TransMessenger Transfection Reagent Handbook 14TransMessenger Transfection Reagent Handbook 15TransMessenger Transfection Reagent Handbook 16TransMessenger Transfection Reagent Handbook 17TransMessenger Transfection Reagent Handbook 18TransMessenger Transfection Reagent Handbook 19TransMessenger Transfection Reagent Handbook 20TransMessenger Transfection Reagent Handbook 21TransMessenger Transfection Reagent Handbook 22TransMessenger Transfection Reagent Handbook 23TransMessenger Transfection Reagent Handbook 24TransMessenger Transfection Reagent Handbook 25QIAshredder Homogenizer 2
(Date:7/28/2014)... Roald Amundsen became the first man to reach the ... years later, an international team of scientists led by ... proven that air pollution from industrial activities arrived long ... from widely spaced locations around the Antarctic continent, including ... and precise reconstruction to date of lead pollution over ...
(Date:7/27/2014)... in vitro study has revealed that nicotine and cotinine, ... caused by a certain carcinogen in smoke. , The ... of tobacco leaves and ultimately ends up in the ... lung and liver, where it is activated by a ... in mice has revealed that nicotine can partially interfere ...
(Date:7/27/2014)... that wiped them out if it had taken place ... A fresh study using up-to-date fossil records and improved ... narrative of the prehistoric creatures, demise, some 66 million ... million years before a 10km-wide asteroid struck what is ... extensive volcanic activity, changing sea levels and varying temperatures. ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2
... to make proteins, key building blocks of all organisms, ... instructions for assembling them. An Iowa State ... marking where these instructions are located in a cell,s ... Journal of Biological Chemistry , Michael Shogren-Knaak, assistant professor ...
... Service scientists have completed a study on a beetle that ... attacked 67 percent of the oak trees in an area ... in the current issue of The Pan-Pacific Entomologist ... so rare it does not even have an accepted common ...
... of Eve to the venomous murder of the mighty Thor, ... of mischief and misery. The worldwide prominence of ... to the serpentbut why, when so few of us have ... Davis, anthropology professor Lynne A. Isbell suggests, lies in the ...
Cached Biology News:New Southern California beetle killing oaks 2
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
... small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental animals. Automatic Calibration with ... ... ... ...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Biology Products: